An international team of researchers including scientists from the Mayo Clinic and the University of Zurich have shown that tolvaptan, a drug already used to treat low blood sodium levels in patients with heart failure and liver problems, may be a promising new treatment for PKD. The findings are the culmination of 15 years of … Continue reading Tolvaptan Slows Kidney Growth in PKD
Skip to content
UKRO – University Kidney Research Organization
Together We Build a Kidney